financetom
Business
financetom
/
Business
/
Terra Balcanica Points To "Unique Geological and Jurisdictional Potential" of Europe Assets After Dundee Precious Metals Move
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Terra Balcanica Points To "Unique Geological and Jurisdictional Potential" of Europe Assets After Dundee Precious Metals Move
Jun 13, 2025 12:56 PM

03:34 PM EDT, 06/13/2025 (MT Newswires) -- Terra Balcanica Resources (TERA.CN) on Friday highlighted the "unique geological and jurisdictional potential" of its own Bosnia and Herzegovina assets after the much bigger Dundee Precious Metals ( DPMLF ) moved to acquire a neighboring producer in the region.

Earlier Friday DPM said it had agreed to buy the UK's Adriatic Metals plc for an implied equity value of approximately $1.3 billion. Upon completion of the transaction, DPM will acquire 100% of the Vares operation in Bosnia and Herzegovina, a producing silver-lead-zinc-gold underground mine.

In Bosnia and Herzegovina, Terra is advancing its Viogor-Zanik polymetallic project expected to see the Phase III drilling campaign start in the next two weeks.

Dr. Aleksandar Miskovic, the President and CEO of Terra, in a statement said: "From the beginning, Terra's operational focus was aimed at the highly prolific Western Tethyan Metallogenic Belt as it extends over the western Balkans."

He added: "Today's major announcement of a mine located only 80 km west of our flagship polymetallic targets at Chumavichi and Brezani is a testament to both amazing rate of advancement of Adriatic's Vares mine but also the mineral resource riches of the jurisdiction in which we proudly operate. Although comparatively early in our corporate development, Terra's next steps aim to drill-confirm the size potential of the Brezani Sb-Ag fault-hosted mineralization that could indicate the same order of magnitude of ore resources as seen at Vares."

Terra was unchanged at $0.10 a share; DPM was up more than 4%.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved